Scientists are hopeful about a new mRNA cancer vaccine developed by Merck & Co. and Moderna Inc., which has shown success in preventing melanoma from returning and could usher in a new era of cancer vaccines. This development brings researchers closer to using vaccines to train the immune system to destroy cancer cells.

Moderna and Merck & Co. have reported positive study results for a new cancer therapy, marking a potential significant advance in cancer treatment and drawing attention to the implications for vaccine skeptics.

Merck & Co., Inc. held its Q2 earnings call, highlighting key financial results and business updates for the quarter.

An article discusses whether Merck & Co., Inc. (MRK) is strengthening its vaccine portfolio with the recent approval of its new Capvaxive vaccine.

New analyst reports have been published, providing detailed insights and evaluations for a diverse group of major companies across various sectors. These reports offer financial analysis and outlooks for firms including Waste Management, Chevron, and Merck & Co.

An analysis explores the factors that make Merck & Co. (MRK) a potential investment opportunity.

Merck & Co. Inc. is highlighted as one of the top low-risk, high-growth stocks for investors to consider buying at the moment.

Merck & Co., Inc. (MRK) has been granted FDA Priority Review for its KEYTRUDA regimen in the treatment of muscle-invasive bladder cancer.

Jim Cramer suggests that Merck & Co. is likely to be an outperformer if the economy enters a slowdown triggered by an oil shock.

Merck & Co. (MRK) is implementing measures to mitigate the impact of the upcoming loss of exclusivity for its drug KEYTRUDA.

MSD (known as Merck & Co., Inc. in the US and Canada) today announces the arrival in Greece of a new innovative pneumococcal conjugate vaccine for adults.

Merck & Co. saw its stock advance, driven by robust sales of its drug Keytruda and favorable results from recent clinical trials.

Scientists are hopeful about a new mRNA cancer vaccine developed by Merck & Co. and Moderna Inc., which has shown success in preventing melanoma from returning. This development brings researchers closer to using vaccines to train the immune system to destroy cancer cells.

This report summarizes the leading Wall Street analyst research calls for Thursday, covering various companies including Alphabet, Analog Devices, Crown Castle, Ebay, and Merck & Co., among others.

Merck & Co., Inc. published its Q2 2026 earnings call summary, reporting on its financial performance and business updates for the second quarter.

An analysis explores whether Merck & Co. (MRK) is considered one of the best cheap stocks for beginner investors.

Merck & Co. has chosen Salesforce AI CRM to develop a comprehensive 360-degree animal health platform.

This article discusses the sentiment of Wall Street analysts regarding Merck & Co. stock, examining their recommendations and outlook for the company's performance.

CNN provides an analysis of the stock quote, current price, and future forecast for MRK (Merck & Co.). This report offers insights into the company's market performance.

An earnings preview for Merck & Co.'s upcoming quarterly report has been released, offering insights into what investors can expect from the pharmaceutical giant.

Merck & Co. (MRK) is being highlighted as a top affordable stock choice, praised for its robust earnings growth potential.

Citi has increased its price target for Merck & Co. (MRK) to $125 from $120.

An article compares the stock performance of Merck & Co. against other companies in the healthcare sector.

A new mRNA cancer vaccine developed by Merck & Co. and Moderna Inc. continues to show promise in preventing melanoma recurrence, with a recent breakthrough suggesting it could usher in a new era of cancer vaccines.

A potential partnership between Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD) is being explored as a possible new engine for growth in the pharmaceutical industry.

This article provides an earnings preview, outlining key expectations and factors to consider ahead of Merck & Co.'s upcoming financial report.

Merck & Co. (MRK) has announced its quarterly dividend payment to shareholders. This is a routine corporate financial update for the pharmaceutical giant.

Jim Cramer commented on Merck & Co.'s stock performance, observing that the stock is beginning to recover.

Merck & Co., Inc. released highlights from its first-quarter earnings call, providing insights into its financial and pharmaceutical developments.

An analysis explores whether pharmaceutical giant Merck & Co. (MRK) is a favorable investment choice during a bear market, evaluating its resilience and potential for growth.

Merck & Co. (MRK) is being evaluated as one of the best consistent dividend stocks available for purchase. This assessment focuses on its reliability for income-seeking investors.

Pharmaceutical giant Merck & Co. has announced its intention to acquire Terns Pharma for $6.7 billion, touting the 'best-in-class' potential of TERN-701 for Chronic Myeloid Leukemia (CML) as a key driver for the deal.

An investment analysis evaluating whether Merck & Co., Inc. (MRK) is a good stock to buy now.

Leerink has increased its price target for Merck & Co. Inc. (MRK), citing potential upside from the company's cancer drug portfolio.

Analysts are providing their perspectives on the future trajectory of Merck & Co., Inc. (MRK), assessing its potential performance.